Tech Company Financing Transactions
Antios Therapeutics Funding Round
On 11/28/2018, Antios Therapeutics landed $25 million in Series A funding from Domain Associates, Lumira Capital and CAM Capital.
Transaction Overview
Company Name
Announced On
11/28/2018
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Domain Associates (Lead Investor)
Lumira Capital (Lead Investor) (Beni Rovinski)
Proceeds Purpose
The proceeds from this financing will be used to develop ATI-2173, Antios' lead oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
575 Pharr Rd. North East 12260
Atlanta, GA 30355
USA
Atlanta, GA 30355
USA
Phone
Undisclosed
Website
Email Address
Overview
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Mayes
Chief Financial Officer
Tamra Adams
Chief Medical Officer
Douglas Mayers
Browse more venture capital transactions:
Prev: 11/28/2018: Keyto venture capital transaction
Next: 11/29/2018: Springboard Retail venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs